Results 131 to 140 of about 36,124 (280)

Population‐Based Identification of Clonal Hematopoiesis Using Peripheral Blood Whole‐Genome Sequencing in Japan

Cancer Science, EarlyView.
Whole‐genome sequencing of ~50,000 individuals from the Tohoku Medical Megabank (TMM) cohort defines the prevalence, mutational landscape, and age dependency of clonal hematopoiesis in the Japanese population, demonstrating overall concordance with clonal hematopoiesis detected in cancer patients.
SungGi Chi, Ikuko N. Motoike, Takao Fujisawa, Yumi Yamaguchi‐Kabata, Takahiro Nobukuni, Kengo Kinoshita, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Kinuko Ohneda, Katsuya Tsuchihara, Yosuke Minami, Riu Yamashita   +12 more
wiley   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, EarlyView.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, EarlyView.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

RARE-30. PEDIATRIC GLIOBLASTOMA IN THE POST-TEMOZOLOMIDE ERA: OUTCOMES AND CHARACTERISTICS [PDF]

, 2019
INTRODUCTION Glioblastoma (GBM) is the most common brain tumor, however, is a rare occurrence in children and is poorly characterized. We evaluated the characteristics and outcomes of pediatric GBM (pGBM).
Aghi, Manish, Berger, Mitchel, Chandra, Ankush, Gupta, Nalin, McDermott, Mike, Oh, Taemin, Shah, Sumedh, Wadhwa, Harsh   +7 more
core  

World Health Organization classification of tumours of the breast 6th edition 2026

Histopathology, EarlyView.
The 6th edition of the World Health Organization Classification of Breast Tumours introduces changes based on recent advances in our understanding of breast biology, developments in diagnostic modalities, identification of specific molecular targets and new treatment regimes.
Cecily Quinn, Puay Hoon Tan, Kimberly H Allison, Edi Brogi, Sunil R Lakhani, Stuart J Schnitt, Stephen B Fox, Shabnam Jaffer, Aysegul Sahin, Roberto Salgado, Anna Sapino, Ernest Kwasi Adjei, Katherine Geiersbach, Thomas H Helbich, Matteo Lambertini, Christos Sotiriou, Jennelle C Hodge, Joseph D Khoury, Bharat Rekhi, Ales Ryska, Gary Tse, Andrew Field, Harshima Wijesinghe, Pavitratha Puspanathan, Christine Giesen, Blanca Iciar Indave Ruiz, Ian Ellis, Dilani Lokuhetty, WCT Standing Editorial Board, Wendy Cooper, Michael Eden, Andrew Field, Vicky Goh, Jennelle C. Hodge, James Kench, Joseph D. Khoury, Katia Leite, Zhiyong Liang, Daichi Maeda, George Netto, Bharat Rekhi, Miguel Reyes Mugica, Brian Rous, Ales Ryska, Shahin Sayed, Antonia Sepulveda, Chanjuan Shi, Gary Tse   +47 more
wiley   +1 more source

Circulating biomarkers predictive of tumor response to cancer immunotherapy [PDF]

, 2019
Introduction: The advent of checkpoint blockade immunotherapy has revolutionized cancer treatment, but clinical response to immunotherapies is highly heterogeneous among individual patients and between cancer types.
Kulkarni, Rajan P., Lee, Ernest Y.
core  

Predictive value of MRD monitoring by BCR clonality in the ZUMA‐7 randomized clinical trial for CAR T therapy in r/r lymphoma

British Journal of Haematology, EarlyView.
Brodie Miles, Daqin Mao, Saran Vardhanabhuti, Davide Bedognetti, Simone Filosto, Rhine Shen   +5 more
wiley   +1 more source

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad, YuZhu Jin, Kai Luo, He Bai, Xudong Zhang, Xu Sun, Zahoor Maheen, Ali Tanveer, Saeed Muddasar Muhammad, Jialin Qu, Guixin Zhang   +10 more
wiley   +1 more source